Swiss National Bank Sells 5,600 Shares of United Therapeutics Corporation $UTHR

Swiss National Bank decreased its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 4.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 123,455 shares of the biotechnology company’s stock after selling 5,600 shares during the period. Swiss National Bank’s holdings in United Therapeutics were worth $51,754,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Norges Bank bought a new stake in shares of United Therapeutics during the second quarter worth about $136,453,000. Invesco Ltd. raised its holdings in shares of United Therapeutics by 90.2% in the 2nd quarter. Invesco Ltd. now owns 884,703 shares of the biotechnology company’s stock worth $254,219,000 after acquiring an additional 419,588 shares during the last quarter. AQR Capital Management LLC lifted its position in United Therapeutics by 40.1% in the 2nd quarter. AQR Capital Management LLC now owns 1,273,161 shares of the biotechnology company’s stock valued at $362,876,000 after acquiring an additional 364,713 shares in the last quarter. Balyasny Asset Management L.P. lifted its position in United Therapeutics by 863.9% in the 2nd quarter. Balyasny Asset Management L.P. now owns 152,727 shares of the biotechnology company’s stock valued at $43,886,000 after acquiring an additional 136,883 shares in the last quarter. Finally, Sofinnova Investments Inc. acquired a new position in United Therapeutics during the 2nd quarter valued at about $34,055,000. 94.08% of the stock is owned by institutional investors.

Insider Activity

In other news, CEO Martine A. Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction on Wednesday, March 11th. The stock was sold at an average price of $539.54, for a total transaction of $5,125,630.00. Following the sale, the chief executive officer directly owned 130 shares in the company, valued at $70,140.20. The trade was a 98.65% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Tommy G. Thompson sold 2,000 shares of the business’s stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $489.42, for a total transaction of $978,840.00. Following the completion of the transaction, the director directly owned 8,480 shares in the company, valued at $4,150,281.60. This trade represents a 19.08% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 338,947 shares of company stock worth $165,516,573. 10.30% of the stock is owned by insiders.

Wall Street Analyst Weigh In

UTHR has been the subject of a number of recent research reports. Jefferies Financial Group reissued a “buy” rating on shares of United Therapeutics in a report on Monday, March 2nd. TD Cowen raised their target price on United Therapeutics from $525.00 to $575.00 and gave the company a “buy” rating in a report on Wednesday, February 25th. Bank of America reiterated a “neutral” rating on shares of United Therapeutics in a report on Wednesday, February 25th. Cantor Fitzgerald increased their price target on United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a research report on Thursday. Finally, UBS Group raised their price objective on United Therapeutics from $655.00 to $705.00 and gave the company a “buy” rating in a research note on Thursday, March 5th. Nine investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $548.09.

United Therapeutics Stock Down 2.2%

United Therapeutics stock opened at $532.82 on Friday. United Therapeutics Corporation has a 52 week low of $266.98 and a 52 week high of $548.12. The company’s 50 day moving average price is $485.89 and its two-hundred day moving average price is $458.53. The stock has a market cap of $23.35 billion, a P/E ratio of 19.10, a P/E/G ratio of 1.96 and a beta of 0.84.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 EPS for the quarter, beating analysts’ consensus estimates of $6.78 by $0.92. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The company had revenue of $790.20 million during the quarter, compared to the consensus estimate of $814.80 million. During the same period last year, the business posted $6.19 earnings per share. United Therapeutics’s revenue was up 7.4% on a year-over-year basis. On average, equities analysts anticipate that United Therapeutics Corporation will post 24.48 EPS for the current year.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.